Engitix Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 61

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $25.1M

  • Investors
  • 5

Engitix General Information

Description

Developer of a therapeutic discovery platform designed to develop predictive models of human biology using the extracellular matrix. The company offers human-derived extracellular matrix scaffolds, advanced computational tools, and three-dimensional translational systems, enabling pharmaceutical researchers and healthcare developers to create safer and more effective therapies for chronic and life-threatening diseases.

Contact Information

Website
www.engitix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, The WestWorks
  • 195 Wood Lane
  • London W12 7FQ
  • England, United Kingdom
+44 020
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4th Floor, The WestWorks
  • 195 Wood Lane
  • London W12 7FQ
  • England, United Kingdom
+44 020

Engitix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Engitix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A2) 09-Apr-2026 $25.1M Completed Pre-Clinical Trials
6. Later Stage VC (Series A1) 08-Jan-2026 Completed Pre-Clinical Trials
5. Later Stage VC (Series A) 18-Dec-2025 Completed Pre-Clinical Trials
4. Later Stage VC 31-Jan-2022 Completed Pre-Clinical Trials
3. Angel (individual) 19-Nov-2018 Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2016 Completed Startup
To view Engitix’s complete valuation and funding history, request access »

Engitix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 963,000 $0.000133 $6.97 $6.97 1x $6.97 16.72%
To view Engitix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Engitix Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Engitix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4204086-A1 Anti-fibrotic combination Inactive 25-Aug-2020
GB-202013270-D0 Anti-fibrotic combination Inactive 25-Aug-2020
US-20230312751-A1 Anti-fibrotic combination Inactive 25-Aug-2020
WO-2022043381-A1 Anti-fibrotic combination Inactive 25-Aug-2020
WO-2019122351-A1 Tissue-specific human bioinks for the physiological 3d-bioprinting of human tissues for in vitro culture and transplantation Inactive 22-Dec-2017 A61L27/20
To view Engitix’s complete patent history, request access »

Engitix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Engitix Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Dompé Corporation Minority
Netherton Investments Venture Capital Minority
UCL Ventures University Minority
University College London University
LabCentral Accelerator/Incubator
To view Engitix’s complete investors history, request access »

Ready to get started?

Request a free trial

Engitix FAQs

  • When was Engitix founded?

    Engitix was founded in 2016.

  • Where is Engitix headquartered?

    Engitix is headquartered in London, United Kingdom.

  • What is the size of Engitix?

    Engitix has 61 total employees.

  • What industry is Engitix in?

    Engitix’s primary industry is Discovery Tools (Healthcare).

  • Is Engitix a private or public company?

    Engitix is a Private company.

  • What is the current valuation of Engitix?

    The current valuation of Engitix is .

  • What is Engitix’s current revenue?

    The current revenue for Engitix is .

  • How much funding has Engitix raised over time?

    Engitix has raised $143M.

  • Who are Engitix’s investors?

    Dompé, Netherton Investments, UCL Ventures, University College London, and LabCentral have invested in Engitix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process